Table 8:

Primary Treatments of Prostate Cancers Between Trials and Study Arms

	American PLCO RCT (Age 55–74 Years)		European ERSPC RCT (Core Age 55–69 Years)
	Screen Group, % (n = 4,250)	Control Group, % (n = 3,815)	Screen Group, % (n = 6,963)	Control Group, % (n = 5,396)
Prostatectomy	40	36.6	33.7	23.9
Radiotherapy	21.2	20.8	19.6	14.5
Radiation and hormone therapy	18.4	21.3	8.7	19.2
Hormone therapy	7.1	8.6	8.8	19.6
Active surveillance	NR	NR	23	16
No known curative	11.5	10.6	NR	NR

Abbreviations: ERSPC, European Randomized Study of Screening for Prostate Cancer; NR, not reported; PLCO, Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; RCT, randomized controlled trial.

Sources: For PLCO, Schroder et al, 2012 (55); for ERSPC, Andriole et al, 2012. (48)